Swiss Pharmaceuticals Company Roche Selects Indiana for New Plant

Swiss pharmaceuticals company Roche announced that it will invest $50 billion into the U.S. in the next five years, including a new manufacturing facility for continuous glucose monitoring in Indiana.

The investments further strengthen Roche’s already significant U.S. footprint with 13 manufacturing and 15 research and development sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs,  as well as 1,000 jobs at new and expanded facilities.

As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight U.S. states. In addition to the new facility in Indiana, the investment will include: 

• Expanded and upgraded U.S. manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
• A state-of-the-art gene therapy manufacturing facility in Pennsylvania
• A new 900,000 square-foot manufacturing center to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)
• A new R&D center in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as hub for our new cardiovascular, renal and metabolism research and development efforts
• Significant expansion and upgrading of our existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana and California

“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”